12:00 AM
Apr 08, 2013
 |  BC Week In Review  |  Company News  |  Sales & Marketing

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to the Biocodex USA subsidiary of Laboratoires Biocodex. Apricus received a $1.5 million upfront payment and is eligible for double-digit, tiered royalties on Totect sales through 2016. Apricus acquired the topoisomerase II inhibitor, which is...

Read the full 363 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$30 USD
More Info >